A...Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to Dabrafenib and Placebo as First-Line ...

Printer-friendly versionSend by emailPDF version

Name

Glaxosmithkline

Anticipated Amount

373 515.00

Activity Type

Clinical Trial

Award Type

Contract

Date

March 23, 2012 to December 21, 2014

Award Number

005322-00001

Sponsor Award Number

MEK115306

Award Contacts

Name

Cranmer,Lee D

Title

Principal Investigator

Unit

Cancer Center Division

UA@Work is produced by University Communications

888 N. Euclid Ave., Ste. 413 (or) 
P.O. Box 210158, Tucson, AZ 85721

T 520.621.1877  F 520.626.4121

Feedback

2018 © The Arizona Board of Regents on behalf of the University of Arizona